Amgen Shadow Pricing Revealed In New Emails Unveiled By House Oversight

By John Wilkerson / October 1, 2020 at 11:46 AM
On day two of the House Oversight Committee’s drug pricing hearing, Democrats released details on three more drug makers’ pricing practices, including Amgen’s use of shadow pricing for Enbrel. The committee on Thursday (Oct. 1) released reports detailing the pricing practices of Amgen, Mallinckrodt and Novartis. On Wednesday, the committee released similar reports on Bristol Myers Squibb/Celgene and Teva. Many of the themes are similar across the companies probed in the committee’s 18-month drug-pricing investigation: free-wheeling price hikes to meet...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.